Smart blood tests may let lung cancer patients take chemo holidays

NCT ID NCT07058519

Recruiting now Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 32 times

Summary

This study is for people with a specific type of advanced lung cancer (EGFR mutation-positive). After initial treatment with the drug osimertinib plus chemotherapy, doctors will use a simple blood test to look for cancer DNA. If the DNA disappears, patients may be able to stop chemotherapy temporarily and take only osimertinib, with regular blood monitoring. The goal is to see if this personalized approach can keep the cancer under control while giving patients a break from chemotherapy side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC EGFRM NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITING

Shanghai, Shanghai Municipality, 200030, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC EGFRM NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC EGFRM NON-SMALL CELL LUNG CANCER (NSCLC)